{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:10:39Z","timestamp":1789229439687,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12928-025-01087-9","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:39:00Z","timestamp":1737074340000},"page":"327-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of procedural and patient-related risks on 1-year outcomes for patients treated with 1-month dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation"],"prefix":"10.1007","volume":"40","author":[{"given":"Ryutaro","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5960-7806","authenticated-orcid":false,"given":"Masaru","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Niiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Ishisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorihiko","family":"Koeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwao","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Morino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REIWA investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"3","key":"1087_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCINTERVENTIONS.111.967463","volume":"5","author":"T Tada","year":"2012","unstructured":"Tada T, et al. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI\/CABG Registry Cohort-2. Circ Cardiovasc Interv. 2012;5(3):381\u201391.","journal-title":"Circ Cardiovasc Interv"},{"issue":"17","key":"1087_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino G, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"1087_CR3","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","volume":"43","author":"M Valgimigli","year":"2022","unstructured":"Valgimigli M, et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022;43(33):3100\u201314.","journal-title":"Eur Heart J"},{"issue":"6","key":"1087_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","volume":"81","author":"F Gragnano","year":"2023","unstructured":"Gragnano F, et al. P2Y(12) inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol. 2023;81(6):537\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1087_CR5","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","volume":"67","author":"U Baber","year":"2016","unstructured":"Baber U, et al. Coronary thrombosis and major bleeding after PCI With drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67(19):2224\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1087_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008708","volume":"7","author":"M Natsuaki","year":"2018","unstructured":"Natsuaki M, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. J Am Heart Assoc. 2018;7(11): e008708.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"1087_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12928-020-00694-y","volume":"35","author":"M Ishida","year":"2020","unstructured":"Ishida M, et al. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. Cardiovasc Interv Ther. 2020;35(4):398\u2013404.","journal-title":"Cardiovasc Interv Ther"},{"issue":"6","key":"1087_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1253\/circj.CJ-24-0091","volume":"88","author":"M Ishida","year":"2024","unstructured":"Ishida M, et al. One-month dual antiplatelet therapy followed by P2Y(12) inhibitor monotherapy after biodegradable polymer drug-eluting stent implantation\u2014the REIWA region-wide registry. Circ J. 2024;88(6):876\u201384.","journal-title":"Circ J"},{"issue":"5","key":"1087_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84(5):831\u201365.","journal-title":"Circ J"},{"issue":"5","key":"1087_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.010384","volume":"14","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, et al. Very short dual antiplatelet therapy after drug-eluting stent implantation in patients who underwent complex percutaneous coronary intervention: insight from the STOPDAPT-2 trial. Circ Cardiovasc Interv. 2021;14(5): e010384.","journal-title":"Circ Cardiovasc Interv"},{"issue":"24","key":"1087_CR11","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414\u201327.","journal-title":"JAMA"},{"issue":"18","key":"1087_CR12","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1056\/NEJMoa2216607","volume":"388","author":"JM Lee","year":"2023","unstructured":"Lee JM, et al. Intravascular imaging-guided or angiography-guided complex PCI. N Engl J Med. 2023;388(18):1668\u201379.","journal-title":"N Engl J Med"},{"issue":"24","key":"1087_CR13","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn JY, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428\u201337.","journal-title":"JAMA"},{"issue":"10205","key":"1087_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0140-6736(19)31877-X","volume":"394","author":"JF Iglesias","year":"2019","unstructured":"Iglesias JF, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394(10205):1243\u201353.","journal-title":"Lancet"},{"issue":"5","key":"1087_CR15","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.4244\/EIJ-D-18-00392","volume":"14","author":"S Buccheri","year":"2018","unstructured":"Buccheri S, et al. Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. EuroIntervention. 2018;14(5):e562\u20139.","journal-title":"EuroIntervention"},{"issue":"9","key":"1087_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jcin.2017.02.037","volume":"10","author":"T Rab","year":"2017","unstructured":"Rab T, et al. Current Interventions for the left main bifurcation. JACC Cardiovasc Interv. 2017;10(9):849\u201365.","journal-title":"JACC Cardiovasc Interv"},{"key":"1087_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.amjcard.2023.02.027","volume":"195","author":"A Tobe","year":"2023","unstructured":"Tobe A, et al. Ischemic and bleeding outcomes in patients who underwent percutaneous coronary intervention with chronic kidney disease or dialysis (from a Japanese nationwide registry). Am J Cardiol. 2023;195:37\u201344.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1087_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.007133","volume":"12","author":"M Faggioni","year":"2019","unstructured":"Faggioni M, et al. Influence of baseline anemia on dual antiplatelet therapy cessation and risk of adverse events after percutaneous coronary intervention. Circ Cardiovasc Interv. 2019;12(4): e007133.","journal-title":"Circ Cardiovasc Interv"},{"key":"1087_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ahj.2020.01.014","volume":"223","author":"F Costa","year":"2020","unstructured":"Costa F, et al. A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. Am Heart J. 2020;223:44\u20137.","journal-title":"Am Heart J"},{"key":"1087_CR20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-24-0481","author":"JK Han","year":"2024","unstructured":"Han JK, et al. Renal function-stratified comparison of short- and long-term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with third-generation drug-eluting stents- post hoc analysis from the HOST-IDEA randomized clinical trial. Circ J. 2024. https:\/\/doi.org\/10.1253\/circj.CJ-24-0481.","journal-title":"Circ J"},{"issue":"1","key":"1087_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12928-020-00651-9","volume":"36","author":"H Watanabe","year":"2021","unstructured":"Watanabe H, et al. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Cardiovasc Interv Ther. 2021;36(1):91\u2013103.","journal-title":"Cardiovasc Interv Ther"},{"issue":"15","key":"1087_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","volume":"387","author":"D Perera","year":"2022","unstructured":"Perera D, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387(15):1351\u201360.","journal-title":"N Engl J Med"},{"issue":"16","key":"1087_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","volume":"374","author":"EJ Velazquez","year":"2016","unstructured":"Velazquez EJ, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511\u201320.","journal-title":"N Engl J Med"},{"issue":"10367","key":"1087_CR24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938\u201352.","journal-title":"Lancet"},{"issue":"3","key":"1087_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","volume":"8","author":"JS Aguilar-Gallardo","year":"2022","unstructured":"Aguilar-Gallardo JS, Correa A, Contreras JP. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):311\u201321.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"1087_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","volume":"138","author":"IS Anand","year":"2018","unstructured":"Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80\u201398.","journal-title":"Circulation"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01087-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-025-01087-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01087-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:50:46Z","timestamp":1742032246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-025-01087-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1007\/s12928-025-01087-9","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masaru Ishida has received lecture honoraria (BIOTRONIK Japan, Boston Scientific Japan, Daiichi-Sankyo, FUKUDA DENSHI, Japan Lifeline, Terumo Corporation). Takenori Ishisone has received lecture honoraria (Boston Scientific Japan, Daiichi-Sankyo, Japan Lifeline, Orbus Neich). Tomonori Itoh has received lecture honoraria (Daiichi Sankyo, Novartis). Yoshihiro Morino has received unrestricted research grants (Boston Scientific Japan, Japan Lifeline, Terumo) and lecture honoraria (Boston Scientific Japan, Daiichi-Sankyo, Terumo). None of the other authors have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Iwate Medical University, IRB Committee reference No. MH2019-042.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB information"}}]}}